Keyword: Taiho Pharmaceutical

Taiho, Otsuka and Chugai wins KRAS-focused licensing deals. Biocon Biologics nabs PE funding before planned IPO. Mark Alles joins Antengene's board.

Biogen and Eisai defend Alzheimer's drug; Taiho and Servier's Lonsurf shows positive gastric cancer data; J&J pays $2.1 billion for Japan's Ci:z.

China fines vaccine scandal-hit Changsheng $1.3 billion; Merck and Samsung bail on a Lantus biosim; Taiho grows VC fund to sixfold.

Not all Big Pharma's businesses in emerging markets are doing so well, Fosun is buying a smaller stake in Gland, Taiho and Arcus ink cancer option deal.

A month after Daiichi Sankyo announced plans for a major investment in cancer drug production, Japanese compatriot Otsuka said it is planning to do the same thing.